Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial

Journal of Heart and Lung Transplantation

Volumn 30, Issue 9, 2011, Pages 990-996

  Finlen Copeland, C Ashley ^a   Davis, W Austin ^a   Snyder, Laurie D ^a   Banks, Missy ^b   Avery, Robin ^c   Davis, R Duane ^a   Palmer, Scott M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

bronchiolitis obliterans syndrome; cytomegalovirus; lung transplantation; valganciclovir

Indexed keywords

ALEMTUZUMAB; GANCICLOVIR; MEPREDNISONE; PREDNISOLONE; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL THERAPY; BLOOD CELL COUNT; BRONCHOSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LONG TERM CARE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; VIREMIA; VIRUS PNEUMONIA;

EID: 80051469766     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.02.017     Document Type: Article

References (16)

1. L.D. Snyder, C.A. Finlen Copeland, W.J. Turbyfill, D. Howell, D.A. Willner, and S.M. Palmer Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation Am J Respir Crit Care Med 181 2010 1391 1396
2. D.M. Zuk, A. Humar, J.G. Weinkauf, D.C. Lien, R.G. Nador, and D. Kumar An international survey of cytomegalovirus management practices in lung transplantation Transplantation 90 2010 672 676
3. S.M. Palmer, A.P. Limaye, and M. Banks Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial Ann Intern Med 152 2010 761 769
4. A.P. Limaye, R. Bakthavatsalam, and H.W. Kim Late onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis Transplantation 78 2004 1390 1396 (Pubitemid 39507981)
5. A.D. Humar, D. Kumar, and J. Preiksaitis A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients Am J Transplant 5 2005 1462 1468 (Pubitemid 40839439)
6. A.P. Limaye, R. Bakthavatsalam, and H.W. Kim Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis Transplantation 81 2006 1645 1652 (Pubitemid 43948296)
7. A.C. Kalil, A.G. Freifeld, E.R. Lyden, and J.A. Stoner Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy PLoS One 4 2009 e5512
8. L.D. Snyder, C.A. Finlen Copeland, S.S. Lin, R.D. Davis, and S.M. Palmer Lung transplantation at Duke University Medical Center Clinical Transpl 2007 99 111
9. C. Chmiel, R. Speich, and M. Hofer Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation Clin Infect Dis 46 2008 831 839 (Pubitemid 351417183)
10. S.M. Palmer, D.C. Grinnan, B.D. Reams, M.P. Steele, R.H. Messier, and R.D. Davis Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir Clin Transplant 18 2004 179 185 (Pubitemid 38404649)
11. M.R. Zamora Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation Transpl Infect Dis 3 suppl 2 2001 49 56 (Pubitemid 34073657)
12. M.R. Zamora, M.R. Nicolls, and T.N. Hodges Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation Am J Transplant 4 2004 1635 1642 (Pubitemid 39312297)
13. P. Jaksch, B. Zweytick, and H. Kerschner Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy J Heart Lung Transplant 28 2009 670 675
14. G.P. Westall, N.A. Mifsud, and T. Kotsimbos Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity Am J Transplant 8 2008 1749 1754
15. L.D. Snyder, R. Medinas, and C. Chan Polyfunctional cytomegalovirus- specific immunity in lung transplant recipients receiving valganciclovir prophylaxis Am J Transplant 11 2011 553 560
16. L. Zafrani, L. Truffaut, and H. Kreis Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study Am J Transplant 9 2009 1816 1825